Tanespimycin (17-AAG)

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Cited by 20 Publications

Mol Cell, 2013, 50(3):368-78

PubMed: 23583076

J Exp Med, 2012, 209(2):259-73

PubMed: 22271575

P Natl Acad Sci USA, 2011, 108(18):7535-40

PubMed: 21502504

Mol Cancer, 2014, 15:30

PubMed: 24927996

Br J Pharmacol, 2017, 174(5):409-423

PubMed: 28052321

ACS Chem Biol, 2014, 9(10):2237-41

PubMed: 25140805

Biochim Biophys Acta, 2013, 1830(11):5184-92

PubMed: 23850472

Biochim Biophys Acta, 2012, 1823(4):911-9

PubMed: 22306003

J Biol Chem, 2012, 287(53):44109-20

PubMed: 23144451

J Nat Prod, 2011, 74(6):1491-9

PubMed: 21553813

Mol Cell Biol, 2013, 33(12):2375-87

PubMed: 23572559

Am J Respir Cell Mol Biol, 2013, 10.1165/rcmb.2013-0214OC

PubMed: 24303801
Exp Gerontol, 2014, 52:55-69

PubMed: 24486130

Insect Mol Biol, 2014, 23(6):720-32

PubMed: 25060629

Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7

PubMed:

Oncotarget, 2015, 51: S659-S660

PubMed:

Julius Maximilians Universit, 2014, Kumari G

PubMed:

Oncotarget, 2014, 5(12):4269-82

PubMed: 24962213

Eukaryot Cell, 2012, 11(11):1324-32

PubMed: 22822234

Age (Dordr), 2012, 35(3):549-62

PubMed: 22252435

9 Customer Reviews

(A) Cell lines were seeded in 96-well plates and treated with 10 nM of 17-AAG for 72 h. Cell survival was analyzed using CellTiter-Glo. Both parental H3122 cells (red bar) and H3122 CR cells (blue bar) show sensitivity to 17-AAG. (B) Suppression of ALK signaling by 17-AAG in resistant H3122 CR cells. H3122 parental and resistant cells were exposed to increasing concentrations of 17-AAG for 6 h.

PNAS, 2011, 108: 7535-40. Tanespimycin (17-AAG) purchased from Selleck.

(A) Treatment of DIPG cells with an HSP90 inhibitor, 17-AAG, resulted in decreased invasion toward SVZ hNPC CM at high doses. (B) Cell viability of DIPG cells treated with increasing doses of 17-AAG, by the CellTiter-Glo assay.

Cell, 2017, 170(5):845-859.e19. Tanespimycin (17-AAG) purchased from Selleck.
SKBR3 cells were treated with FW-04-806 at 10, 20, 40 uM for 24 h; 17AAG was used as a positive control at 1 and 2 uM. Hsp70, Hsp90, and Cdc37 protein level were analyzed with western blotting using relevant antibodies.

Mol Cancer 2014 13, 150. Tanespimycin (17-AAG) purchased from Selleck.

Western blot analysis of immunoprecipitated Hsp90/BIP complexes in MOLT-4 (T-ALL) and RS4;11 (B-ALL) treated for 22 h with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. 500 μg of protein lysates were immunoprecipitated with anti-Hsp90 antibody. Relative Induction values (Rel.Ind.) were obtained by normalizing to Hsp90 bands density. 17-AAG: tanespimycin.

Oncotarget, 2015, 51: S659-S660. Tanespimycin (17-AAG) purchased from Selleck.
Co-IP analyses of direct interaction between HSP90 and HIF-1α in 17-AAG (5 μM)-treated HSCs using antibodies against HSP90, HIF-1α or IgG (n = 2).

Br J Pharmacol, 2017, 174(5):409-423. Tanespimycin (17-AAG) purchased from Selleck.

Treatment with an Hsp90 inhibitor results in a dose-dependent decrease in complex IV activity. A, because Hsp90 levels were reduced by 80%, in PINK1 null dopaminergic neuronal cells, the effects of specific inhibition of Hsp90 using 17-AAG were analyzed in wild-type neuronal cells. Both complex IV activity and Hsp60 levels were decreased significantly in 17-AAG-treated cells in a dose-dependent manner. B, in contrast, 17-AAG treatment did not affect expression of Hsp90 and LRPPRC.

J Biol Chem 2012 287, 44109-20. Tanespimycin (17-AAG) purchased from Selleck.
UPR modulators destabilize mSmoM2. NIH 3T3 cells expressing mSmoM2 protein were treated with HSP90 inhibitors 17-AAG (50 uM and 100 uM) and SNX-2112 (25 uM and 50 uM) and the proteasome inhibitor bortezomib (25 uM and 50 uM) for 4 h prior to lysis. DMSO was the vehicle control. Western blotting of whole-cell lysates revealed mSmoM2 protein to be destabilized in response to HSP-90 inhibitors but not in response to bortezomib. Tubulin was the loading control. CHOP results indicate ER stress.

Mol Cell Biol 2013 33(12), 2375-87. Tanespimycin (17-AAG) purchased from Selleck.

Hsp90 is up-regulated during aging. Whole-cell extracts were prepared from young (PD 20) and old (PD 40) HFSN1 cells. c HFSN1 cells (PD 40) were treated with different concentration of the Hsp90 inhibitor (17-AAG) and then re-incubated for 24 h. Whole-cell extracts were prepared and analyzed by western blot using the indicated antibodies.

Age 2013 35, 549-62. Tanespimycin (17-AAG) purchased from Selleck.
Four types of the colon cancer cells with indicated K-Ras phenotype were incubated with indicated concentration of 17-AAG for 24 h, which were then analyzed for protein expression by WB.

Oncotarget 2014 5, 4269-82. Tanespimycin (17-AAG) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description

Features

Displays very low toxicity toward normal cells.

Targets

HSP90 ^[1]
(Cell-free assay)

5 nM

In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. ^[1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. ^[2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
A549	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWD2RpFZUUN3ME2wMlAxODNyMzFOwG0>	NFGyd2FUSU6JRWK=
IST-MEL1	NILyfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7GRVlvUUN3ME2wMlAxODRyNzFOwG0>	MVzTRW5ITVJ?
NCI-SNU-1	MoPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrId4hxUUN3ME2wMlAxOjB5IN88US=>	MoDGV2FPT0WU
FADU	NHu4W25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zGTGlEPTB;MD6wNFIxQSEQvF2=	NF;YV\|lUSU6JRWK=
C32	MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnK2TWM2OD1yLkCwN\|A1KM7:TR?=	MkKxV2FPT0WU
D-566MG	NYX0eZRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoH3TWM2OD1yLkCwN\|kh\|ryP	NV3DSFJ3W0GQR1XS
LXF-289	NWjBVlJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrIZY5KSzVyPUCuNFA1OTlizszN	M1zGcHNCVkeHUh?=
HGC-27	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDTO4VKSzVyPUCuNFA2OSEQvF2=	MoOyV2FPT0WU
RPMI-7951	NXnZ[plST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXOZlA2UUN3ME2wMlAxPzF5IN88US=>	MX7TRW5ITVJ?
HSC-3	MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;xVmlEPTB;MD6wNFkzQSEQvF2=	M3fXZ3NCVkeHUh?=
MIA-PaCa-2	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLJN5JKSzVyPUCuNFExODlizszN	NU\DdnN1W0GQR1XS
KS-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTBwMEGzOVUh\|ryP	NILUdFVUSU6JRWK=
CAL-51	MnvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7HTWM2OD1yLkCxOFA2KM7:TR?=	MUnTRW5ITVJ?
MDA-MB-361	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTBwMEG0PVUh\|ryP	NXTSN3hEW0GQR1XS
TI-73	MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwMEG3PVYh\|ryP	MX;TRW5ITVJ?
AGS	NVT2e2NyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHO4SGRKSzVyPUCuNFE6OzhizszN	NIjCSGNUSU6JRWK=
NCI-H460	NILrd\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nEO2lEPTB;MD6wNVk4PCEQvF2=	NV\nXW9vW0GQR1XS
A204	NH7EXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjXblhKSzVyPUCuNFIzPDlizszN	MnHVV2FPT0WU
CHL-1	NID1W3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{iydGlEPTB;MD6wNlI2OSEQvF2=	MoDIV2FPT0WU
DU-4475	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTBwMEKyOlEh\|ryP	MUPTRW5ITVJ?
CGTH-W-1	NIHqVm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDKTWM2OD1yLkCyN\|Q6KM7:TR?=	M2K4W3NCVkeHUh?=
HCC2218	M2CyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTBwMEK0PVQh\|ryP	M3XROXNCVkeHUh?=
A2780	MmnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIexRmVKSzVyPUCuNFI2OzFizszN	MkXpV2FPT0WU
NCI-H720	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\BWWlEPTB;MD6wNlU1PiEQvF2=	MofmV2FPT0WU
NCI-N87	M4XCVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnLbVVXUUN3ME2wMlAzPTl\|IN88US=>	MWHTRW5ITVJ?
CHP-212	MkHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTBwMEK2Nlgh\|ryP	MmfWV2FPT0WU
NCI-H23	NXHvcY82T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWCyPYlHUUN3ME2wMlAzPjZ3IN88US=>	MYrTRW5ITVJ?
D-263MG	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrLTWM2OD1yLkCyO\|g3KM7:TR?=	NWnFNXRoW0GQR1XS
ME-180	M1rhT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3iTWM2OD1yLkCyPFkyKM7:TR?=	M1nK[nNCVkeHUh?=
SW982	M2rOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\jeWlEPTB;MD6wNlk6QSEQvF2=	MY\TRW5ITVJ?
OE19	NYfFc3Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfORYZKUUN3ME2wMlA{ODd5IN88US=>	M{X2UXNCVkeHUh?=
SK-LU-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTs[Zd7UUN3ME2wMlA{ODh{IN88US=>	MYXTRW5ITVJ?
H4	MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1O3VmlEPTB;MD6wN\|A6KM7:TR?=	MWfTRW5ITVJ?
HT-144	M{HFd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTBwMEOwPVMh\|ryP	MmXiV2FPT0WU
SK-UT-1	NV3QTJpGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTIT2dKSzVyPUCuNFMyPzhizszN	NVnRT3BzW0GQR1XS
D-336MG	NIXld3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fuXWlEPTB;MD6wN\|MxQSEQvF2=	Ml;iV2FPT0WU
MDA-MB-175-VII	NEnSPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTBwMEOzOVQh\|ryP	MUHTRW5ITVJ?
GAMG	M4PxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjNO3BIUUN3ME2wMlA{PDN3IN88US=>	M{W3R3NCVkeHUh?=
CP50-MEL-B	NIXsb5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vNTmlEPTB;MD6wN\|Q2KM7:TR?=	NYfnUXR{W0GQR1XS
OVCAR-5	MnrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHxUJFKSzVyPUCuNFM1QCEQvF2=	MoXnV2FPT0WU
SK-MES-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPoTWM2OD1yLkCzOlA3KM7:TR?=	NIXlb5JUSU6JRWK=
VM-CUB-1	MkLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2qwfWlEPTB;MD6wN\|Y2PyEQvF2=	NFzQcJpUSU6JRWK=
WM-115	MnmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrqTG1PUUN3ME2wMlA{PzZ{IN88US=>	NVvueld2W0GQR1XS
DSH1	NVLTcnJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX2yTm1yUUN3ME2wMlA{QDB5IN88US=>	Mn3QV2FPT0WU
Becker	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmn4TWM2OD1yLkCzPFg2KM7:TR?=	MoLZV2FPT0WU
SW962	NXi1XZdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTBwMEO5OFUh\|ryP	MlfwV2FPT0WU
TYK-nu	NVvIW3NQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrTRnNKSzVyPUCuNFM6QDVizszN	MWrTRW5ITVJ?
HO-1-N-1	NGjUS\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXWXnlKSzVyPUCuNFQxOjFizszN	MXjTRW5ITVJ?
T98G	NFLyZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXW5bVlwUUN3ME2wMlA1OTB\|IN88US=>	Ml;vV2FPT0WU
ACN	NHHxO2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DoZ2lEPTB;MD6wOFE3OiEQvF2=	NVi5[mV[W0GQR1XS
SW780	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUniRZo5UUN3ME2wMlA1OjB\|IN88US=>	NFfz[ldUSU6JRWK=
Detroit562	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrjOoxKSzVyPUCuNFQzOzlizszN	MXPTRW5ITVJ?
BB49-HNC	NFTaN21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3iTWM2OD1yLkC0NlQ{KM7:TR?=	MX;TRW5ITVJ?
HN	M2TWWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\RNGlEPTB;MD6wOFI4OiEQvF2=	M2n5b3NCVkeHUh?=
H9	MlHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFr6VVFKSzVyPUCuNFQ{PzFizszN	MVrTRW5ITVJ?
VA-ES-BJ	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jN[WlEPTB;MD6wOFQ1PyEQvF2=	NV7s[29jW0GQR1XS
MEL-JUSO	MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwMES0O\|Uh\|ryP	MXjTRW5ITVJ?
BT-474	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrlZVZ5UUN3ME2wMlA1PSEQvF2=	NXv1fZlwW0GQR1XS
CaR-1	NXzuO4lGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDwU4c4UUN3ME2wMlA1PTR7IN88US=>	NHrYVmFUSU6JRWK=
PSN1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrtSmdKSzVyPUCuNFQ3ODNizszN	M1rUfHNCVkeHUh?=
KYSE-510	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3lTWM2OD1yLkC0OlQ6KM7:TR?=	MYHTRW5ITVJ?
KP-4	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonQTWM2OD1yLkC0O\|U{KM7:TR?=	MWrTRW5ITVJ?
KYSE-410	NF\6ZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkD5TWM2OD1yLkC0O\|czKM7:TR?=	M4rVcnNCVkeHUh?=
G-402	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjFbnI2UUN3ME2wMlA1Pzh7IN88US=>	NF6zOVZUSU6JRWK=
DOK	NXPreHp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzzcIN3UUN3ME2wMlA1QTB{IN88US=>	NHXwXW9USU6JRWK=
COR-L88	MmrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEH4eVFKSzVyPUCuNFQ6OTJizszN	NETGcYhUSU6JRWK=
SKG-IIIa	MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HpNmlEPTB;MD6wOFk5PiEQvF2=	Ml3CV2FPT0WU
AN3-CA	NI\X[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPyTWM2OD1yLkC1JO69VQ>?	NFy4TFNUSU6JRWK=
SW48	NIHad5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfofIVKSzVyPUCuNFUxOzlizszN	MV3TRW5ITVJ?
YKG-1	NHrUW3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33nWWlEPTB;MD6wOVA4OSEQvF2=	Mmj3V2FPT0WU
KYSE-150	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTm[ZFKSzVyPUCuNFUzOzVizszN	NGO4W3lUSU6JRWK=
HuO-3N1	M2DwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHmzcHdKSzVyPUCuNFUzOzdizszN	Mn:wV2FPT0WU
LB1047-RCC	NYnDfJN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;1dIFKSzVyPUCuNFUzQTZizszN	MYnTRW5ITVJ?
NCI-H2030	NXPocHB[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2[zTGlEPTB;MD6wOVQyPCEQvF2=	NYnvUpR1W0GQR1XS
YH-13	MkjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonjTWM2OD1yLkC1O\|IzKM7:TR?=	NYO4fWJ1W0GQR1XS
5637	NVu0WFd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{P6[WlEPTB;MD6wOVc1KM7:TR?=	M1LGZnNCVkeHUh?=
LOXIMVI	NYfhfFV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrlNI1yUUN3ME2wMlA2QDd{IN88US=>	NFzrR3ZUSU6JRWK=
GT3TKB	Ml\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXi4ZXYyUUN3ME2wMlA2QTR{IN88US=>	NF7I[\|RUSU6JRWK=
TCCSUP	M2niTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\iTWM2OD1yLkC1PVY1KM7:TR?=	NXeyeG45W0GQR1XS
EPLC-272H	M2fkUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1z3V2lEPTB;MD6wOlIxPSEQvF2=	Mn7CV2FPT0WU
LU-99A	MkTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Moq2TWM2OD1yLkC2NlM4KM7:TR?=	NHLrPWFUSU6JRWK=
NCI-H1755	M{LGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7oTWM2OD1yLkC2N\|QyKM7:TR?=	MWjTRW5ITVJ?
KM12	NIPpfGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzYZXh6UUN3ME2wMlA3OzR6IN88US=>	MoO3V2FPT0WU
SF295	NEW2ZXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3uSIJKSzVyPUCuNFY1PTJizszN	M3vFR3NCVkeHUh?=
MZ2-MEL	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\xbYtKSzVyPUCuNFY2PTNizszN	MUTTRW5ITVJ?
HEC-1	NH7kVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37JRmlEPTB;MD6wOlU5QCEQvF2=	NWLoNFhJW0GQR1XS
SW684	NX\NR294T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDGTWM2OD1yLkC2OVkyKM7:TR?=	MnLPV2FPT0WU
SF539	NIHXbJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzzcGlKSzVyPUCuNFY3QDFizszN	Mnq2V2FPT0WU
GMS-10	M{P4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwME[2PVkh\|ryP	MXXTRW5ITVJ?
MV-4-11	NGW0O4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jDRWlEPTB;MD6wOlgxOyEQvF2=	NFr0cXFUSU6JRWK=
HT-29	NUjheI15T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTBwME[5NVkh\|ryP	MX7TRW5ITVJ?
23132-87	NE[0[W1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvtXXRKSzVyPUCuNFY6PSEQvF2=	MWTTRW5ITVJ?
SW620	NYn3Z3BDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\UVmlEPTB;MD6wO\|AzPiEQvF2=	Mkm1V2FPT0WU
HCC1806	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LvdWlEPTB;MD6wO\|E{OSEQvF2=	Mlm1V2FPT0WU
Hs-578-T	M2\v[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7OTWM2OD1yLkC3NlA5KM7:TR?=	NFe2emZUSU6JRWK=
A2058	MnO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDDTWM2OD1yLkC3NlI5KM7:TR?=	NGXLVFZUSU6JRWK=
MEL-HO	NV3iTlNzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfkTWM2OD1yLkC3NlU2KM7:TR?=	M{iwWHNCVkeHUh?=
HCC2998	NIrlemZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXGUItRUUN3ME2wMlA4OzR5IN88US=>	MYjTRW5ITVJ?
HuO9	NVKzfFFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrRTmVKSzVyPUCuNFc2QDlizszN	Mmj0V2FPT0WU
CAL-39	M2rGNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{S5XGlEPTB;MD6wO\|c3PiEQvF2=	NWrCNIFlW0GQR1XS
M14	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17wfWlEPTB;MD6wO\|kyOyEQvF2=	NYPadnhoW0GQR1XS
BFTC-909	NW\LVIRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{O0eWlEPTB;MD6wO\|k3QSEQvF2=	MWjTRW5ITVJ?
TE-11	NGTaU4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXGTWM2OD1yLkC3PVk3KM7:TR?=	NVLMdpJRW0GQR1XS
TGBC1TKB	MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1raVmlEPTB;MD6wPFA1OyEQvF2=	M3q1fnNCVkeHUh?=
L-363	MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLlRVJKSzVyPUCuNFgzODZizszN	M3O2OnNCVkeHUh?=
A431	M{Tmbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnDXGpuUUN3ME2wMlA5OjFizszN	M2Pme3NCVkeHUh?=
MKN45	MorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTBwMEiyNVkh\|ryP	NFTSRm1USU6JRWK=
HT-1080	NUnJcI9uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzZTWM2OD1yLkC4OFM6KM7:TR?=	MVjTRW5ITVJ?
OVCAR-8	NU\JdpI1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvMcGtWUUN3ME2wMlA5PjJ{IN88US=>	NXTCcFNMW0GQR1XS
LCLC-97TM1	NEHFS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nsbGlEPTB;MD6wPFczQCEQvF2=	M1PWOXNCVkeHUh?=
M059J	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;QTWM2OD1yLkC5NFI4KM7:TR?=	MYLTRW5ITVJ?
SK-MEL-2	NEL6SGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTBwMEmwOkDPxE1?	NFXPWJNUSU6JRWK=
TE-1	MmjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvKZY43UUN3ME2wMlA6OjB2IN88US=>	M4rOVXNCVkeHUh?=
KYSE-180	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwMEmyOlIh\|ryP	NEXO[2FUSU6JRWK=
D-247MG	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XYc2lEPTB;MD6wPVQ2PSEQvF2=	MkTnV2FPT0WU
8-MG-BA	NU\1WoVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\3TWM2OD1yLkC5OFczKM7:TR?=	NUGyXnpoW0GQR1XS
NCI-H1792	M2nkcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fKZWlEPTB;MD6wPVYyQCEQvF2=	NITqcplUSU6JRWK=
MCF7	M2DUW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTBwMEm2O\|ch\|ryP	MUnTRW5ITVJ?
NCI-H2122	NYOyZlNGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3X3eWlEPTB;MD6wPVc1PSEQvF2=	M1PSVHNCVkeHUh?=
EFO-27	NYCwZpBlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPpbY1lUUN3ME2wMlA6QTl5IN88US=>	MWDTRW5ITVJ?
LB2241-RCC	Mn3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjzfVUyUUN3ME2wMlExODV2IN88US=>	MVHTRW5ITVJ?
SN12C	NVqwUWlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nMSmlEPTB;MD6xNFExPyEQvF2=	M3HwN3NCVkeHUh?=
A498	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYC0WolwUUN3ME2wMlExOThizszN	MVPTRW5ITVJ?
PANC-03-27	NWPCW5I6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTBwMUCyPFYh\|ryP	NYfmdpMyW0GQR1XS
NCI-H1581	NH;WW3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILHc5FKSzVyPUCuNVAzQSEQvF2=	MWXTRW5ITVJ?
U-87-MG	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTBwMUCzNFch\|ryP	M2\QVHNCVkeHUh?=
G-401	MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TwfmlEPTB;MD6xNFM2OyEQvF2=	M2HaTnNCVkeHUh?=
SiHa	NW\1cFAxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo[wTWM2OD1yLkGwOFg3KM7:TR?=	MVzTRW5ITVJ?
U251	MnHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLqU5Z1UUN3ME2wMlExPTJ3IN88US=>	NHH0d\|hUSU6JRWK=
MMAC-SF	NUjTNXhzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTBwMUC1N\|Eh\|ryP	MkPVV2FPT0WU
BB65-RCC	NV3sc3NzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmniTWM2OD1yLkGwOVU1KM7:TR?=	MXjTRW5ITVJ?
NKM-1	NYOxWVBMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml6zTWM2OD1yLkGwOlY3KM7:TR?=	NU[yZXRGW0GQR1XS
HD-MY-Z	MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrNclVKSzVyPUCuNVA5PzNizszN	NE\LZllUSU6JRWK=
TGBC11TKB	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnL[mxKSzVyPUCuNVA6ODNizszN	M{\4[HNCVkeHUh?=
COLO-679	NGXw[\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnMcZRKSzVyPUCuNVEzOTFizszN	MYjTRW5ITVJ?
TE-8	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXywT286UUN3ME2wMlEyOjZ2IN88US=>	MVPTRW5ITVJ?
SK-MEL-28	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;qUFFKSzVyPUCuNVE{OjFizszN	MV3TRW5ITVJ?
SH-4	NELjV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3HTWM2OD1yLkGxN\|U3KM7:TR?=	NY\1WHB{W0GQR1XS
KALS-1	M1jRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXy3bGgyUUN3ME2wMlEyOzl\|IN88US=>	NVHQTHVwW0GQR1XS
RKO	NIi0VFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rHbWlEPTB;MD6xNVc3PCEQvF2=	M3zpUHNCVkeHUh?=
OMC-1	NFnYUVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nQPGlEPTB;MD6xNVc6PyEQvF2=	M3:zVnNCVkeHUh?=
BT-549	NXjISZE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTBwMUG3PVkh\|ryP	Mn\HV2FPT0WU
NCI-H28	NWjUUoxMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTBwMUG4NVch\|ryP	Ml[wV2FPT0WU
RXF393	MlXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTXZ2czUUN3ME2wMlEyQTh{IN88US=>	NVvFVY57W0GQR1XS
COLO-829	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDmTWM2OD1yLkGyNFA2KM7:TR?=	NGT3d2ZUSU6JRWK=
HMV-II	M4XpTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYi5[Gh1UUN3ME2wMlEzODJizszN	MYnTRW5ITVJ?
SW1990	NYP4e3hyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnCdHdmUUN3ME2wMlEzOTV5IN88US=>	NH\Hd\|lUSU6JRWK=
NCI-H1437	NUD4N\|RlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkT0TWM2OD1yLkGyNVU4KM7:TR?=	MVzTRW5ITVJ?
SNB75	M{TnfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnaNYZxUUN3ME2wMlEzOTZ7IN88US=>	MVfTRW5ITVJ?
EW-3	NY\OTXhST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfEe25KSzVyPUCuNVI3PjFizszN	NEHEc5lUSU6JRWK=
SAS	NHnPTmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;5PIFKSzVyPUCuNVI3QSEQvF2=	MljiV2FPT0WU
NCI-H1666	NVu2SHVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvuTYRKSzVyPUCuNVI4PzRizszN	NH7Ge4ZUSU6JRWK=
A375	M4fkfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofwTWM2OD1yLkGyO\|c5KM7:TR?=	NU[0[3c{W0GQR1XS
CAMA-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLRRXhKSzVyPUCuNVI6OjRizszN	MYLTRW5ITVJ?
HuP-T4	M3f6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\ub2pVUUN3ME2wMlEzQTR\|IN88US=>	M2f0PXNCVkeHUh?=
NCI-H292	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo[3TWM2OD1yLkGzNVEh\|ryP	M3;hU3NCVkeHUh?=
PC-14	NYX3VGtJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPhTWM2OD1yLkGzNlEyKM7:TR?=	MXzTRW5ITVJ?
BPH-1	NG\LRYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXOXFZKSzVyPUCuNVM1OSEQvF2=	MUnTRW5ITVJ?
GAK	MoC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGiye3dKSzVyPUCuNVM2PjdizszN	M3jE[HNCVkeHUh?=
VMRC-RCZ	M3nkXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrrTWM2OD1yLkGzO\|YzKM7:TR?=	M4DsO3NCVkeHUh?=
SK-MEL-24	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIm5eGpKSzVyPUCuNVM5PyEQvF2=	M4\XUXNCVkeHUh?=
LB831-BLC	NIfhRmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTBwMUO4PFMh\|ryP	NI\aPIpUSU6JRWK=
NCI-H2452	NUPZS3V1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvu[nJWUUN3ME2wMlE{QTV4IN88US=>	Mk\oV2FPT0WU
RT-112	Ml2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjsUWtKSzVyPUCuNVQxOzVizszN	NWPlUZI6W0GQR1XS
GP5d	M4CwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHCdZNKSzVyPUCuNVQyODRizszN	MWHTRW5ITVJ?
LC-2-ad	NYGydVJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{i3dWlEPTB;MD6xOFEzOSEQvF2=	M1:wT3NCVkeHUh?=
MPP-89	M{j6OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojuTWM2OD1yLkG0NVI2KM7:TR?=	M2jmVnNCVkeHUh?=
NUGC-3	M1zOUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlS3TWM2OD1yLkG0OFc5KM7:TR?=	Ml\lV2FPT0WU
GI-1	M4fzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7wTWM2OD1yLkG0OVU5KM7:TR?=	NVHDb\|ZZW0GQR1XS
HCC1419	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVj3eW9ZUUN3ME2wMlE1PTd4IN88US=>	Mm\hV2FPT0WU
SW1573	NEm5OZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zzR2lEPTB;MD6xOFc2QCEQvF2=	MXfTRW5ITVJ?
NCI-H2347	MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XPTGlEPTB;MD6xOFg{QSEQvF2=	MV3TRW5ITVJ?
Mewo	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3vTWM2OD1yLkG0PFg6KM7:TR?=	MlTJV2FPT0WU
639-V	MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPVW2wzUUN3ME2wMlE2ODF\|IN88US=>	MkHnV2FPT0WU
AsPC-1	M{PVeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTBwMUWyNlUh\|ryP	MmnRV2FPT0WU
NCI-H1648	M{jYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXvV5BVUUN3ME2wMlE2OjN{IN88US=>	Mkn2V2FPT0WU
786-0	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnmZ5FOUUN3ME2wMlE2OzhzIN88US=>	NX7VVVkyW0GQR1XS
ETK-1	M3;vTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnhSZh4UUN3ME2wMlE2QSEQvF2=	MUfTRW5ITVJ?
BxPC-3	NUP6elg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPnTWM2OD1yLkG1PVY3KM7:TR?=	MlftV2FPT0WU
CAL-62	NFvNTo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPuU3dKSzVyPUCuNVYyPjlizszN	MkTJV2FPT0WU
HCC1937	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPTXoZKSzVyPUCuNVYzPzVizszN	MoK3V2FPT0WU
NCI-H1299	MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPFOJdKSzVyPUCuNVYzQDVizszN	M2LQbHNCVkeHUh?=
SW1088	M1vGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXG1fnJRUUN3ME2wMlE3PDF\|IN88US=>	MXfTRW5ITVJ?
FTC-133	MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTBwMU[1OEDPxE1?	MWrTRW5ITVJ?
OC-314	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTBwMU[2PUDPxE1?	NHHFSmZUSU6JRWK=
SCC-9	NXjoSpg4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\3TWM2OD1yLkG2O\|E3KM7:TR?=	M2iyPXNCVkeHUh?=
HT-1376	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI[4VWNKSzVyPUCuNVY6OzZizszN	NXjLZWVzW0GQR1XS
U-2-OS	M3j5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7CTWM2OD1yLkG3NVc{KM7:TR?=	MVzTRW5ITVJ?
COLO-824	NV\wTZVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfNTWM2OD1yLkG3Nlk1KM7:TR?=	MoHwV2FPT0WU
BB30-HNC	NGjxNWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTBwMUezN{DPxE1?	MV\TRW5ITVJ?
NCI-H2087	NWPUUJVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1u3N2lEPTB;MD6xO\|M3QCEQvF2=	MnHUV2FPT0WU
NCI-H2170	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPOTWM2OD1yLkG3OVM3KM7:TR?=	NHrZ[IVUSU6JRWK=
SK-OV-3	NX70[YhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjaXIhKSzVyPUCuNVc2PzFizszN	M2T2WHNCVkeHUh?=
MZ7-mel	NWW3VIk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPiTIdKSzVyPUCuNVc3PDlizszN	NFTENY1USU6JRWK=
NCI-H650	M2nab2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTlbJVKSzVyPUCuNVc3QDJizszN	MVnTRW5ITVJ?
KOSC-2	M{C3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTBwMUe3N\|Qh\|ryP	MWHTRW5ITVJ?
SCC-4	MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXW3[HRTUUN3ME2wMlE4Pzd5IN88US=>	MYTTRW5ITVJ?
MDA-MB-157	NWPnSHdzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHq0dIZKSzVyPUCuNVgxQDJizszN	MlHmV2FPT0WU
KYSE-520	NFvuW\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzkOYJkUUN3ME2wMlE5OiEQvF2=	M2\KOnNCVkeHUh?=
LK-2	MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rjR2lEPTB;MD6xPFMxOyEQvF2=	M3r6VXNCVkeHUh?=
KNS-81-FD	NHv1d2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LXfmlEPTB;MD6xPFM6PCEQvF2=	M1;LVXNCVkeHUh?=
IGROV-1	NUPEcIk1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPwTWM2OD1yLkG4OFQ{KM7:TR?=	NIj2PHBUSU6JRWK=
DEL	NGG5S5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\NSHFKSzVyPUCuNVg1PSEQvF2=	MUfTRW5ITVJ?
NCI-H1395	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXi5NplZUUN3ME2wMlE5Pjh{IN88US=>	NXryfnNvW0GQR1XS
JEG-3	MoKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTBwMUi3NFUh\|ryP	NF7xcVFUSU6JRWK=
BCPAP	MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTBwMUi4O\|Ih\|ryP	M3\VZ3NCVkeHUh?=
CAL-27	NHPkPG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILLOpZKSzVyPUCuNVkxOjJizszN	MV\TRW5ITVJ?
RD	NGHl[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vXbGlEPTB;MD6xPVEyOyEQvF2=	MlL6V2FPT0WU
RVH-421	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPPNHlKSzVyPUCuNVkyOTZizszN	M3nCOHNCVkeHUh?=
Capan-2	MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGT1UnRKSzVyPUCuNVkzPTZizszN	M4ft[XNCVkeHUh?=
COLO-680N	M2XGcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTBwMUmzOlQh\|ryP	NXe4bZNrW0GQR1XS
NCI-H1650	NEDVT2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HVVmlEPTB;MD6yNFA2PyEQvF2=	NWPzT3lYW0GQR1XS
SBC-5	NHfKO45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PpfGlEPTB;MD6yNFEyQCEQvF2=	NGTLU4lUSU6JRWK=
U031	NU\SOnZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzRS4ZKSzVyPUCuNlA2PDdizszN	MXHTRW5ITVJ?
S-117	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HEUWlEPTB;MD6yNFU3PCEQvF2=	MW\TRW5ITVJ?
DoTc2-4510	Ml:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TvfWlEPTB;MD6yNFc3QSEQvF2=	MkfKV2FPT0WU
AM-38	MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nzbWlEPTB;MD6yNFg1QCEQvF2=	NIPrTmZUSU6JRWK=
A172	NYf3c\|RFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPueoJZUUN3ME2wMlIyODJ{IN88US=>	Mnv1V2FPT0WU
HPAF-II	NWTFWGpXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI[2PFBKSzVyPUCuNlEzPjRizszN	NWPud21HW0GQR1XS
769-P	M1Pwfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDDTWM2OD1yLkKxNlgh\|ryP	MlL3V2FPT0WU
MFE-280	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorFTWM2OD1yLkKxNlk5KM7:TR?=	M1;DSnNCVkeHUh?=
TE-9	M33YS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTBwMkG3PFYh\|ryP	NF\uUFlUSU6JRWK=
C2BBe1	NWDIXGJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\rTWM2OD1yLkKyNVkh\|ryP	NWn0O5pHW0GQR1XS
EoL-1-cell	M1vjbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LO[GlEPTB;MD6yNlIxOyEQvF2=	MlPaV2FPT0WU
G-361	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTBwMkK2PFIh\|ryP	MnGzV2FPT0WU
KYSE-270	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPPfHhoUUN3ME2wMlI{ODh2IN88US=>	NG\L[o1USU6JRWK=
TK10	M2Szd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mof5TWM2OD1yLkKzNVE4KM7:TR?=	MkDSV2FPT0WU
ML-2	M{PkZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\mZ3BKSzVyPUCuNlMyOTlizszN	MYLTRW5ITVJ?
MHH-ES-1	NHXvUlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPVTWM2OD1yLkKzOlgyKM7:TR?=	NF:zWIRUSU6JRWK=
BHY	NVPmNXFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{joRmlEPTB;MD6yN\|Y6OSEQvF2=	Mnu2V2FPT0WU
LS-513	NGrSdmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfOV3VQUUN3ME2wMlI{QTZzIN88US=>	NIjaeJBUSU6JRWK=
COLO-678	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjiTWM2OD1yLkK0NFQ1KM7:TR?=	NXzKPXI4W0GQR1XS
NCI-H747	Mof3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTBwMkSxOlkh\|ryP	NFm1Z3hUSU6JRWK=
K5	NF\ndJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nuPGlEPTB;MD6yOFM5KM7:TR?=	NXnmbnJtW0GQR1XS
OS-RC-2	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTBwMkS1NFkh\|ryP	M4nKcXNCVkeHUh?=
KINGS-1	M3nTdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTBwMkS1Nlkh\|ryP	MYrTRW5ITVJ?
SCC-25	MkHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjZV4t1UUN3ME2wMlI1PTZ\|IN88US=>	MWrTRW5ITVJ?
CAPAN-1	M2fCPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwMkS3PFMh\|ryP	MWrTRW5ITVJ?
ESS-1	NFP0Vo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYr1PZE3UUN3ME2wMlI1QDB3IN88US=>	NETC[5JUSU6JRWK=
TE-6	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTHToZsUUN3ME2wMlI2PzVizszN	NILVUllUSU6JRWK=
LB2518-MEL	M{DycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXxbWk{UUN3ME2wMlI2Pzd5IN88US=>	M4SxPXNCVkeHUh?=
COLO-800	Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwMkW4NVIh\|ryP	NXPmUHNLW0GQR1XS
LU-134-A	MmDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHITWM2OD1yLkK2NVM3KM7:TR?=	MUPTRW5ITVJ?
NCI-H1155	M3LrdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPDblF[UUN3ME2wMlI3OTZ{IN88US=>	MVTTRW5ITVJ?
MFM-223	M4f0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHMXlNGUUN3ME2wMlI3OzZ\|IN88US=>	MmGwV2FPT0WU
HTC-C3	NV;4bYc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLjS4dlUUN3ME2wMlI3PTB4IN88US=>	MnHBV2FPT0WU
HCT-116	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTBwMk[1PVkh\|ryP	MWHTRW5ITVJ?
Ca-Ski	MljHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILDOnlKSzVyPUCuNlY3PzhizszN	MWjTRW5ITVJ?
SBC-1	NGXQXpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;vdIZKSzVyPUCuNlY4PDJizszN	NGXjbHFUSU6JRWK=
NB69	NF;Yb4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPtenI6UUN3ME2wMlI4ODh5IN88US=>	MV7TRW5ITVJ?
J82	M{LrU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPsdJNKSzVyPUCuNlczPjVizszN	NVLldG5ZW0GQR1XS
U-118-MG	NIfXdWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjWTVBKSzVyPUCuNlc2PzlizszN	NVrpVJlyW0GQR1XS
NCI-H1355	NWTIfJZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYKyU4RMUUN3ME2wMlI5ODd2IN88US=>	MnnxV2FPT0WU
NCI-H1048	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnSVolKSzVyPUCuNlg6PTZizszN	M{Lve3NCVkeHUh?=
SW954	Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEL4NnFKSzVyPUCuNlkzOjdizszN	MX;TRW5ITVJ?
NMC-G1	NVmzSoh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTBwMkmyO\|ch\|ryP	MkHXV2FPT0WU
SW1710	NVrXSI5GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLPXpZLUUN3ME2wMlI6PDl2IN88US=>	MkLRV2FPT0WU
KY821	M3jnUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfHSndKSzVyPUCuNlk5PzJizszN	M1zEfXNCVkeHUh?=
HCC38	MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHSTWM2OD1yLkOwNFc5KM7:TR?=	MVLTRW5ITVJ?
NCI-SNU-5	M{fueGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknyTWM2OD1yLkOwOVQh\|ryP	M3;KS3NCVkeHUh?=
ES8	MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\YOVVTUUN3ME2wMlMxPzh2IN88US=>	Ml6yV2FPT0WU
COLO-792	MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTBwM{GyOVEh\|ryP	MUHTRW5ITVJ?
BFTC-905	M1LwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTBwM{G1NlEh\|ryP	Ml\NV2FPT0WU
ChaGo-K-1	NGfYPWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTBwM{G3NVUh\|ryP	M{HqWnNCVkeHUh?=
Daoy	M2\BZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTBwM{G3NlMh\|ryP	NH\PdHNUSU6JRWK=
SJSA-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwM{G4OFch\|ryP	MoHTV2FPT0WU
KNS-62	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4W0UWlEPTB;MD6zNlA5QCEQvF2=	NFLIclBUSU6JRWK=
CAKI-1	Mo\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXtOXI1UUN3ME2wMlMzOTFzIN88US=>	NWrMOYU5W0GQR1XS
UACC-62	MoD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTBwM{KyNlch\|ryP	M1y2ZXNCVkeHUh?=
HuCCT1	NF;n[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfCTWM2OD1yLkOyNlg{KM7:TR?=	MUjTRW5ITVJ?
CTB-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDsOZBKSzVyPUCuN\|I4PTNizszN	NYHSNFVjW0GQR1XS
NTERA-S-cl-D1	M{nMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTBwM{K4N\|Yh\|ryP	MnfEV2FPT0WU
T-24	NEfRcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLhTWM2OD1yLkOzNVU6KM7:TR?=	MlXWV2FPT0WU
KYSE-70	NFrKTVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYW1S4F{UUN3ME2wMlM{Ojh\|IN88US=>	M133SnNCVkeHUh?=
SW626	MoTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXMTWM2OD1yLkOzOVMzKM7:TR?=	M1nQT3NCVkeHUh?=
LB996-RCC	MlfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrWTWM2OD1yLkOzOlE6KM7:TR?=	MXjTRW5ITVJ?
DMS-273	NVHqN2xrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzBTWM2OD1yLkOzPVE3KM7:TR?=	NYLHfmI{W0GQR1XS
SW1783	M374c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnIb4ZKSzVyPUCuN\|M6QTdizszN	MkTTV2FPT0WU
KU812	Mk[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwM{SwN\|gh\|ryP	NEHBV3lUSU6JRWK=
HSC-2	M4HaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DPN2lEPTB;MD6zOFA2OyEQvF2=	MYDTRW5ITVJ?
A3-KAW	NI\wfWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXHNmpKSzVyPUCuN\|QyPjJizszN	M4T4eHNCVkeHUh?=
COLO-684	Mn7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXf5fZVpUUN3ME2wMlM1PTBzIN88US=>	MoDyV2FPT0WU
NCI-H2405	M1myNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmTvTWM2OD1yLkO0OlMyKM7:TR?=	NHqwc3pUSU6JRWK=
NCI-H2228	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwM{WzOVch\|ryP	MXfTRW5ITVJ?
NB13	NHzhRmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPjNXpKSzVyPUCuN\|Y5OjlizszN	NXrSNG1GW0GQR1XS
no-11	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnn2TWM2OD1yLkO2PVUh\|ryP	MnvwV2FPT0WU
DK-MG	NXfibos2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnHcWNSUUN3ME2wMlM4OTh6IN88US=>	MVHTRW5ITVJ?
NBsusSR	Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlT0TWM2OD1yLkO3Nlg2KM7:TR?=	M2HIT3NCVkeHUh?=
KP-N-YS	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfmTWM2OD1yLkO3OFY{KM7:TR?=	NGjq[XBUSU6JRWK=
CFPAC-1	NUL0SJoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTBwM{e1NVgh\|ryP	MWfTRW5ITVJ?
KARPAS-45	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfuPYxbUUN3ME2wMlM4QDZ{IN88US=>	MYHTRW5ITVJ?
NCI-H1793	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF[1WHBKSzVyPUCuN\|g2OSEQvF2=	M2HuOHNCVkeHUh?=
HCE-T	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDLSZd[UUN3ME2wMlM5PjB\|IN88US=>	MkDuV2FPT0WU
NCI-H520	MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrle3VKSzVyPUCuN\|g4ODNizszN	MWDTRW5ITVJ?
HCC2157	Mkf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHFR5FKSzVyPUCuN\|g4QDFizszN	Mmf4V2FPT0WU
EW-18	NXzuWYpyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTBwM{i5OFEh\|ryP	M3;RWHNCVkeHUh?=
RO82-W-1	M1zuUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTBwM{m2PVkh\|ryP	MYLTRW5ITVJ?
HuP-T3	MmXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XFXGlEPTB;MD60NFE1OyEQvF2=	NVX4c4pSW0GQR1XS
PANC-10-05	M3\JXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3YdZNJUUN3ME2wMlQyOTdizszN	NGS5d41USU6JRWK=
NCI-H1703	M17IW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\MUY1KSzVyPUCuOFE1PDZizszN	NH\kepZUSU6JRWK=
TE-10	NWfhdYRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVO2V4FWUUN3ME2wMlQyPDR5IN88US=>	NYfRN4JXW0GQR1XS
HOS	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF61e3lKSzVyPUCuOFE3QDJizszN	NYK4TFg2W0GQR1XS
LN-405	M1jQV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHPPFlKSzVyPUCuOFE3QDdizszN	NX3VbGlqW0GQR1XS
A427	NW\oPXl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnOeFlQUUN3ME2wMlQyQThzIN88US=>	MmfJV2FPT0WU
CAL-12T	NI\2bHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnr4TWM2OD1yLkSyO\|gh\|ryP	MYTTRW5ITVJ?
SW756	MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;rTWM2OD1yLkS0NVg{KM7:TR?=	M1WwOXNCVkeHUh?=
YAPC	NXjnNmhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlywTWM2OD1yLkS1NFgh\|ryP	NFzZWWFUSU6JRWK=
GOTO	NIjIdIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrSUXpjUUN3ME2wMlQ2OTZizszN	MWjTRW5ITVJ?
C3A	MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfidWFKSzVyPUCuOFU1OzdizszN	NHrDVpVUSU6JRWK=
UM-UC-3	NI\rN\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwNEW0O{DPxE1?	NH3qO\|BUSU6JRWK=
NCI-H1573	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwNEW1Olkh\|ryP	Mne3V2FPT0WU
LS-411N	M1vOXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrhTWM2OD1yLkS2OVI4KM7:TR?=	NHTQeYFUSU6JRWK=
COR-L23	NVjnbXlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXkcVVXUUN3ME2wMlQ3PzZ2IN88US=>	NIHNfndUSU6JRWK=
HCE-4	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1m4b2lEPTB;MD60O\|Q1PiEQvF2=	M1LHVXNCVkeHUh?=
NCI-H2291	NE\RbnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTBwNEe4PVYh\|ryP	NFjNbphUSU6JRWK=
A101D	NFv6b3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvSTWM2OD1yLkS4NFU{KM7:TR?=	MV7TRW5ITVJ?
HT-3	MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfrbpNKSzVyPUCuOFgzOTdizszN	M1H1[3NCVkeHUh?=
HOP-62	NITVcZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HobWlEPTB;MD60PVg3PSEQvF2=	MoXuV2FPT0WU
PC-3	M33JcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3n[oNKSzVyPUCuOVE2ODdizszN	MlfwV2FPT0WU
CTV-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGX5[VZKSzVyPUCuOVI3PjlizszN	M2no[nNCVkeHUh?=
PANC-08-13	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITX[4lKSzVyPUCuOVMyPzdizszN	NHXqRnhUSU6JRWK=
CAL-120	MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmTDTWM2OD1yLkWzN\|k6KM7:TR?=	M4XYWXNCVkeHUh?=
UMC-11	MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDUbmU2UUN3ME2wMlU2OjN2IN88US=>	M{fFNXNCVkeHUh?=
MSTO-211H	M1uyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLXTWM2OD1yLkW1O\|YzKM7:TR?=	NFTJeHVUSU6JRWK=
NCI-H2126	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDs[4h3UUN3ME2wMlU3QDF3IN88US=>	MUTTRW5ITVJ?
SNU-C2B	NUP3Oo8zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4Xab2lEPTB;MD61O\|k4PyEQvF2=	MXTTRW5ITVJ?
DBTRG-05MG	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTBwNUiwOVMh\|ryP	Mn7LV2FPT0WU
MKN1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTBwNUi3PFMh\|ryP	Ml;jV2FPT0WU
ES3	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTBwNUmxNlQh\|ryP	NFH2TGVUSU6JRWK=
OVCAR-3	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\B[2lEPTB;MD61PVM1OSEQvF2=	NYXuUXlZW0GQR1XS
ACHN	NFr2c5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TyR2lEPTB;MD62NFU3QSEQvF2=	MnHKV2FPT0WU
SW872	NHPCPY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHPTWM2OD1yLk[wO\|Y{KM7:TR?=	NVTGVYJbW0GQR1XS
CP66-MEL	M3X3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoG3TWM2OD1yLk[wPVY6KM7:TR?=	NYPt[5lrW0GQR1XS
NCI-H661	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXtO3lxUUN3ME2wMlYyOTB2IN88US=>	MlXjV2FPT0WU
UACC-893	M1zLSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTBwNkO2PFEh\|ryP	NV7kc5pEW0GQR1XS
JVM-3	MknNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTBwNkO4NFQh\|ryP	M1vaeHNCVkeHUh?=
SF268	MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHP2W4ZKSzVyPUCuOlQ{PDlizszN	NHuyRllUSU6JRWK=
OCI-AML2	M2HV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTmUnA4UUN3ME2wMlY2Ozl5IN88US=>	NEPtV5pUSU6JRWK=
RPMI-8226	M{jxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETsN\|lKSzVyPUCuOlY{OjNizszN	NXzmTpViW0GQR1XS
MKN28	NXviWFdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3ZTWM2OD1yLk[2OlI1KM7:TR?=	NFjkcI9USU6JRWK=
MDA-MB-453	M1HRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTtcoVoUUN3ME2wMlY4OThizszN	M2T3VnNCVkeHUh?=
BV-173	MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYT1bYtGUUN3ME2wMlY5Pjd7IN88US=>	M{GyfXNCVkeHUh?=
NCI-H358	NWHIPFBIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjGZYpKSzVyPUCuOlg4OjZizszN	NUTkfJYxW0GQR1XS
NCI-H1651	NUPYXY06T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF65O2JKSzVyPUCuO{DPxE1?	MlXRV2FPT0WU
MDA-MB-415	NYHTc\|FLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nWXmlEPTB;MD63NFgzQSEQvF2=	NVGyO25JW0GQR1XS
8305C	M3vaXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2m3NGlEPTB;MD63NlQ6QCEQvF2=	M4LUOnNCVkeHUh?=
EFM-19	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTBwN{O2O\|Eh\|ryP	NYPMd3d[W0GQR1XS
RERF-LC-MS	NUHJV2w2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTBwN{S2NVMh\|ryP	NGX3c5VUSU6JRWK=
A388	MnnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHGXW03UUN3ME2wMlc3PDZ5IN88US=>	MXrTRW5ITVJ?
GI-ME-N	Mne3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTlTWM2OD1yLke3NlM2KM7:TR?=	MoPwV2FPT0WU
IGR-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfBTldsUUN3ME2wMlc6ODR\|IN88US=>	MVLTRW5ITVJ?
LNCaP-Clone-FGC	MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PlRmlEPTB;MD64NFAxPCEQvF2=	MX7TRW5ITVJ?
SK-MEL-3	M{f5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TGeWlEPTB;MD64NVUxQCEQvF2=	NGnWXnJUSU6JRWK=
UACC-257	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3CTWM2OD1yLkiyNlMyKM7:TR?=	Ml3vV2FPT0WU
OE33	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfRTWM2OD1yLki1NVAyKM7:TR?=	NX:2R3J5W0GQR1XS
QIMR-WIL	NVzIUW01T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkT1TWM2OD1yLki1NVQyKM7:TR?=	MYjTRW5ITVJ?
NCI-H2009	Mlj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDZW5I5UUN3ME2wMlg2OzFzIN88US=>	NHXwWVFUSU6JRWK=
NCI-H522	NFnhVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPTfZVKSzVyPUCuPFc4QDNizszN	NEPhd4NUSU6JRWK=
Saos-2	NF7IUWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3H1WGlEPTB;MD64O\|g4OSEQvF2=	NEPRRVNUSU6JRWK=
NB17	M2CzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTBwOEiwNlUh\|ryP	MUjTRW5ITVJ?
D-392MG	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfWOGRKSzVyPUCuPFk{PTZizszN	M2DjenNCVkeHUh?=
SHP-77	NXLCSXVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTBwOUC0PFUh\|ryP	NG\OUFZUSU6JRWK=
SK-MEL-30	NHL0bYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLIdGhxUUN3ME2wMlkyOTh3IN88US=>	NGDteJRUSU6JRWK=
GCIY	M1Htb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NED0RY1KSzVyPUCuPVE5PDNizszN	MX3TRW5ITVJ?
HCC70	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoX4TWM2OD1yLkmyNFU6KM7:TR?=	NVXxdlQyW0GQR1XS
LU-65	NEHZTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXITWM2OD1yLkmyOVkyKM7:TR?=	Ml:xV2FPT0WU
NCI-H1563	Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHvTWM2OD1yLkm0PFY2KM7:TR?=	M3nI[HNCVkeHUh?=
KURAMOCHI	NFXldINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXL3XXp7UUN3ME2wMlk2OTl{IN88US=>	M2K3enNCVkeHUh?=
PA-1	NGi3fYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{n1NWlEPTB;MD65OVQzPCEQvF2=	NYPZTG4zW0GQR1XS
NOS-1	NEfFUopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULvfGs2UUN3ME2wMlk4PDh7IN88US=>	M{DPdnNCVkeHUh?=
NCI-H69	NHW5Z5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfjNphKSzVyPUCuPVc3OzRizszN	Mn61V2FPT0WU
KYSE-450	M4PEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLqempKSzVyPUCuPVg3OjZizszN	NX7xcpVzW0GQR1XS
8505C	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTBwOUm5PFIh\|ryP	NVS4PZpmW0GQR1XS
TGBC24TKB	M1m0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHK4ZWpKSzVyPUGuNFAxQDRizszN	NYjJZ\|M{W0GQR1XS
PFSK-1	NETrXndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzUPZFKSzVyPUGuNFE1OjhizszN	MV7TRW5ITVJ?
EKVX	MnzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DZdmlEPTB;MT6wN\|EzOSEQvF2=	NHLwOlJUSU6JRWK=
RCM-1	NXfyfo5LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LGU2lEPTB;MT6wOVUxPyEQvF2=	MliyV2FPT0WU
SW900	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1frd2lEPTB;MT6wO\|g{KM7:TR?=	NEL3TVJUSU6JRWK=
D-542MG	M2P3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXW0UmNnUUN3ME2xMlA4QDV3IN88US=>	MXzTRW5ITVJ?
SK-PN-DW	M3O3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTFwMUCwOVYh\|ryP	M4PXenNCVkeHUh?=
NCI-H727	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoS2TWM2OD1zLkGwNVU1KM7:TR?=	MnnOV2FPT0WU
SW837	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTFwMUC5OVQh\|ryP	NVrOZlR{W0GQR1XS
BT-20	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPaUGVKSzVyPUGuNVEzODRizszN	M{nKZ3NCVkeHUh?=
RH-18	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrkSnFpUUN3ME2xMlE{OTB\|IN88US=>	NHvhUZZUSU6JRWK=
TE-12	M{\admdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTFwMUOzN\|Mh\|ryP	MmfFV2FPT0WU
NB10	M4S1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TleWlEPTB;MT6xN\|M1PCEQvF2=	M4\VWnNCVkeHUh?=
AU565	MnezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV34bFI4UUN3ME2xMlE2QTd\|IN88US=>	NXe5[G1wW0GQR1XS
OAW-42	MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfQdGlKSzVyPUGuNVg{ODZizszN	M1XOVnNCVkeHUh?=
DJM-1	M4nvc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrufFBKSzVyPUGuNVk5QDFizszN	NUDLeFZFW0GQR1XS
HH	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTFwMkO4N\|Eh\|ryP	M1:3N3NCVkeHUh?=
LAMA-84	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFi4NItKSzVyPUGuNlc{QTRizszN	NVnzWmxNW0GQR1XS
KNS-42	NX20TYMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3n1cWlEPTB;MT6zNFI6PiEQvF2=	NFe2OYFUSU6JRWK=
NCI-H2052	NVTl[JFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTFwM{C1NFch\|ryP	M4HnV3NCVkeHUh?=
MLMA	MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGntUItKSzVyPUGuN\|I1ODdizszN	NFv2PWxUSU6JRWK=
NB12	NE\kT45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\QUZhKSzVyPUGuN\|U3OzZizszN	NX3IdZU4W0GQR1XS
NCI-H1838	M{HZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnvTWM2OD1zLkO2N\|A3KM7:TR?=	NXnh[otzW0GQR1XS
NCI-H526	NWLt[IdzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLwd\|lOUUN3ME2xMlM4QDV\|IN88US=>	MUfTRW5ITVJ?
LS-123	M4LlNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fk[mlEPTB;MT6zPVA6PCEQvF2=	M2TReHNCVkeHUh?=
HDLM-2	NUHUUlZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmi2TWM2OD1zLkO5NlcyKM7:TR?=	MUjTRW5ITVJ?
MC-IXC	NV;2RmozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIqxU2NKSzVyPUGuOFI{PzFizszN	MmHMV2FPT0WU
HCT-15	M4C0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWf1OFlUUUN3ME2xMlQ{ODZ6IN88US=>	NYixe2ViW0GQR1XS
NCI-H596	NUPMN4Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fVb2lEPTB;MT60OVA3OSEQvF2=	Ml\MV2FPT0WU
ZR-75-30	M{fjTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\Jc\|R2UUN3ME2xMlQ4ODh{IN88US=>	MoG1V2FPT0WU
A704	M{\u[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTFwNk[1OlMh\|ryP	NVn2RVNTW0GQR1XS
OVCAR-4	MmHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;Jd45FUUN3ME2xMlY6PjB5IN88US=>	MkDmV2FPT0WU
SW1417	NIfafo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTFwN{K4OFkh\|ryP	NE\3OWFUSU6JRWK=
CAS-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnuVmpVUUN3ME2xMlc{QTN4IN88US=>	MmHrV2FPT0WU
IST-SL1	NWexbopHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVL4bmo5UUN3ME2xMlc6PzV7IN88US=>	NGrVd3VUSU6JRWK=
A253	NUPQ[o4xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXr2N3htUUN3ME2xMlgzOjN7IN88US=>	NITNbWdUSU6JRWK=
EW-16	M{TmN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF[z[pRKSzVyPUGuPFI5PzVizszN	NHPwUGVUSU6JRWK=
SK-NEP-1	NVn2cWpST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTFwOE[5PFgh\|ryP	MULTRW5ITVJ?
NCI-H226	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPnTWM2OD1zLki5N\|U6KM7:TR?=	MX7TRW5ITVJ?
HOP-92	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3y3eWlEPTB;MT65OlA6QSEQvF2=	NIroN3VUSU6JRWK=
NCI-H441	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;oWoRKSzVyPUKuNFI{OzdizszN	NULV[VJ6W0GQR1XS
LU-139	NV\sc\|A4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXHUmpKSzVyPUKuNFMyOTRizszN	NYjzUmVvW0GQR1XS
SJRH30	Mn76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrvT\|l3UUN3ME2yMlA1OjV\|IN88US=>	M3rQ[3NCVkeHUh?=
MG-63	Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVj2fIU2UUN3ME2yMlE1OTFzIN88US=>	M332d3NCVkeHUh?=
NH-12	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnFOWJIUUN3ME2yMlE2ODB4IN88US=>	MUjTRW5ITVJ?
NB7	NUDXXnVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnJTWM2OD1{LkG5Olc{KM7:TR?=	NHLxeohUSU6JRWK=
LB771-HNC	MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVG1ZVFbUUN3ME2yMlIxPTl3IN88US=>	MmXDV2FPT0WU
HCC1569	NUSxcphvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTJwMkS1PFMh\|ryP	Ml3JV2FPT0WU
D-283MED	NU\VeokzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTJwMkS3PFIh\|ryP	NF2zNZFUSU6JRWK=
J-RT3-T3-5	M4\qW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnTcHFKSzVyPUKuNlU{PTFizszN	MlLaV2FPT0WU
ATN-1	MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnTTWM2OD1{LkOzNFgzKM7:TR?=	NHXDOXBUSU6JRWK=
HCC1954	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfGfWc2UUN3ME2yMlM1PDB6IN88US=>	M13PcHNCVkeHUh?=
SCC-15	MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\EepFKSzVyPUKuN\|k{OTJizszN	MknpV2FPT0WU
COLO-668	Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjXTWM2OD1{LkSzNkDPxE1?	NUXZdpBjW0GQR1XS
LB373-MEL-D	NGPlVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDTfmFKSzVyPUKuOVQ3PzdizszN	M4iwdXNCVkeHUh?=
no-10	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHryV5VKSzVyPUKuOVQ6PDdizszN	MYHTRW5ITVJ?
HT-1197	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTJwNkOxPFgh\|ryP	MnjNV2FPT0WU
DU-145	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnv4TWM2OD1{Lke5NVYzKM7:TR?=	NULs[4hUW0GQR1XS
SK-N-AS	MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vHNWlEPTB;Mj64OFY6OiEQvF2=	NIO4VVRUSU6JRWK=
MOLT-4	NILjc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3TJWWlEPTB;Mj64OVMzOiEQvF2=	NFH0NotUSU6JRWK=
EW-22	NELkWVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWn3WnFWUUN3ME2yMlkzQDRzIN88US=>	MoraV2FPT0WU
DB	NUf5ZmhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTJwOUe3OVkh\|ryP	NYTVTI9kW0GQR1XS
HL-60	MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkn5TWM2OD1\|LkC0N\|c3KM7:TR?=	NUfEUlF5W0GQR1XS
SK-N-DZ	M4DNeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYKzc4dpUUN3ME2zMlA2ODd3IN88US=>	MUTTRW5ITVJ?
NY	M1\YUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjkTWM2OD1\|LkC4OVQzKM7:TR?=	NXzsZoZ5W0GQR1XS
T47D	NF3nfopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTNwMUC1OVgh\|ryP	NE\WeIpUSU6JRWK=
NCI-H2029	NHPhd5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfrcHNHUUN3ME2zMlIzPDd5IN88US=>	MUPTRW5ITVJ?
KARPAS-299	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnhNXhvUUN3ME2zMlI3ODJ5IN88US=>	M4nKdnNCVkeHUh?=
KM-H2	MoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TOW2lEPTB;Mz6zNFY5KM7:TR?=	MYHTRW5ITVJ?
CHP-134	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTNwNEezPUDPxE1?	MkDMV2FPT0WU
22RV1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1W1PWlEPTB;Mz60PVE3QCEQvF2=	NFjNZmZUSU6JRWK=
NB5	Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;ESHBKSzVyPUOuOVA3QDlizszN	MYnTRW5ITVJ?
CW-2	NYTRSGt{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUT1XmQ3UUN3ME2zMlU2OzF2IN88US=>	MmPGV2FPT0WU
EFO-21	NGPweJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknjTWM2OD1\|LkW2PVQh\|ryP	NGCzZpRUSU6JRWK=
HuH-7	NWLENmJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTNwNUi0NVQh\|ryP	M{\x[3NCVkeHUh?=
ALL-PO	NYLsTZhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTNwNkKzN\|Uh\|ryP	NIjlSVRUSU6JRWK=
EM-2	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkH1TWM2OD1\|Lk[5NFEyKM7:TR?=	NUTjPZU5W0GQR1XS
KLE	NGDISlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFn2RmNKSzVyPUOuO\|MxOjlizszN	M4nXXXNCVkeHUh?=
NEC8	NH;COZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTNwOUG4NFgh\|ryP	NUOy[IhGW0GQR1XS
KP-N-YN	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTKXmNKSzVyPUOuPVM1PzZizszN	MXTTRW5ITVJ?
SK-MEL-1	M3q5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTRwMEO1NVgh\|ryP	M2T5R3NCVkeHUh?=
CAL-54	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnWRmJKSzVyPUSuNFU6OSEQvF2=	M4rITnNCVkeHUh?=
MS-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\5TWM2OD12LkG2NVU2KM7:TR?=	MYDTRW5ITVJ?
NCI-H209	M3:z[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFr4VpRKSzVyPUSuNlk6QTlizszN	NHf2d4NUSU6JRWK=
NOMO-1	M4i3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXKTHNJUUN3ME20MlMzOTNzIN88US=>	M2fjb3NCVkeHUh?=
RPMI-2650	M1[zXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFr3ZlNKSzVyPUSuN\|Y{OjdizszN	MWfTRW5ITVJ?
NCI-H810	NYHVeVRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfRbVRHUUN3ME20MlM6PzN4IN88US=>	NF3mb2RUSU6JRWK=
Ca9-22	MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlG1TWM2OD12LkS1OlkyKM7:TR?=	MnXRV2FPT0WU
ES4	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zzW2lEPTB;ND60O\|A6PSEQvF2=	NX3IOXZCW0GQR1XS
ES6	MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVv2[WZPUUN3ME20MlQ6PjV5IN88US=>	NYP5SWlYW0GQR1XS
DMS-114	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHrTWM2OD12LkW0OlkyKM7:TR?=	NVv5U5dYW0GQR1XS
ONS-76	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\0NZhMUUN3ME20MlU4QTVizszN	MVjTRW5ITVJ?
K-562	NHXmZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYqzZYVDUUN3ME20Mlc{QDF2IN88US=>	MnftV2FPT0WU
MHH-NB-11	MojBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGO0WGpKSzVyPUSuO\|U1PjFizszN	MV\TRW5ITVJ?
Calu-3	M1TBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzCd5dKSzVyPUSuO\|g2PDhizszN	M3fnU3NCVkeHUh?=
HT55	NFvoRVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjpe3BbUUN3ME20Mlg1PTR3IN88US=>	MWrTRW5ITVJ?
SK-N-FI	M2PLNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUOxcW9LUUN3ME20Mlg2ODB7IN88US=>	Mn7sV2FPT0WU
ES1	NFj4V5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLFTWM2OD12Lki2NFU4KM7:TR?=	NFrVcmNUSU6JRWK=
SF126	M33pd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jGVmlEPTB;ND65N\|E5PCEQvF2=	M1;lOnNCVkeHUh?=
ES5	M4\4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTVwMUK0Nlch\|ryP	MYDTRW5ITVJ?
LoVo	NWXrRmpKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTVwMUW4O\|Eh\|ryP	MlfiV2FPT0WU
SNU-387	M1rTW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTVwM{KzN\|kh\|ryP	NYjBWm81W0GQR1XS
C8166	M4XEdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7Ie5FsUUN3ME21MlM3OzN7IN88US=>	NGDISZlUSU6JRWK=
LS-1034	NHHBO2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfmTWM2OD13LkSyN\|A4KM7:TR?=	NHi1e2ZUSU6JRWK=
GR-ST	NIDJZ3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkW1TWM2OD13LkWyNlAyKM7:TR?=	NETJW21USU6JRWK=
NCI-H1092	M{KxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTVwN{K4OFMh\|ryP	MlfuV2FPT0WU
647-V	NIfa[HFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXvTWM2OD13Lke0O\|A3KM7:TR?=	MYDTRW5ITVJ?
EW-13	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPnbFlKSzVyPUWuO\|Y3OjdizszN	M3mwcnNCVkeHUh?=
KGN	M4XaNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDLTWM2OD14LkC5PVIyKM7:TR?=	NX6xNGUxW0GQR1XS
D-423MG	MknqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XR[mlEPTB;Nj60NFI5PCEQvF2=	NV36ZoVyW0GQR1XS
ECC10	NEXCb4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MomzTWM2OD15LkGwNVAyKM7:TR?=	MVfTRW5ITVJ?
TE-5	NWG4TJI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTxU2lKSzVyPUeuOFEzQThizszN	MoTvV2FPT0WU
P12-ICHIKAWA	M1;w[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LwfmlEPTB;Nz60OVUzOyEQvF2=	MVXTRW5ITVJ?
NCI-H82	MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTdwNEW3NFEh\|ryP	NFm0OnFUSU6JRWK=
NCI-H1993	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTWfHNMUUN3ME23Mlg{ODZ\|IN88US=>	NF\EV4ZUSU6JRWK=
RH-1	NVzibWdvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{XkcGlEPTB;Nz64OVI1PCEQvF2=	M3rXNXNCVkeHUh?=
SW948	NUm1[Gd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHqTnVKSzVyPUeuPVYxPDlizszN	NUfQ[4plW0GQR1XS
CAL-33	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTdwOUm5N\|gh\|ryP	MnvMV2FPT0WU
U-266	MmfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\HRnZIUUN3ME24MlE2Pzd5IN88US=>	NGXLTodUSU6JRWK=
CAL-72	NFL6dWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHsUIM1UUN3ME24MlIxOzJizszN	MnTCV2FPT0WU
SNU-423	MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH25Z5RKSzVyPUmuN\|Y3PjZizszN	MUnTRW5ITVJ?
KG-1	Mnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDOTWM2OD17LkW4OFU3KM7:TR?=	M3H2bHNCVkeHUh?=
HCC1395	MmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXzb2lKSzVyPUmuPVI{PTJizszN	NE\0VmpUSU6JRWK=
BE-13	M1zKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nkOmlEPTB;MUCuPFg6OiEQvF2=	M2TnV3NCVkeHUh?=
MKN7	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjYWm1KSzVyPUGwMlk4PjVizszN	M3r5PHNCVkeHUh?=
697	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvNPJZKSzVyPUGxMlE1PzJizszN	MmLoV2FPT0WU
LU-135	Mn7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPyZWhKSzVyPUGxMlI{ODdizszN	MnjNV2FPT0WU
ES7	M1m2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTFzLkOzNVMh\|ryP	MlqwV2FPT0WU
SK-HEP-1	NV:wS3hFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFmydGpKSzVyPUGxMlc3PDZizszN	Ml;WV2FPT0WU
BEN	NWDvV4NNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDTTWM2OD1zMT64OVEh\|ryP	NXTVdo05W0GQR1XS
NCI-H1770	NX3adVV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17RfmlEPTB;MUKuNVI3KM7:TR?=	NYfTSZhNW0GQR1XS
SW13	M1P6WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTF{LkG1OFEh\|ryP	M2HOcXNCVkeHUh?=
MZ1-PC	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DMcWlEPTB;MUKuOVQ2OiEQvF2=	Mk\5V2FPT0WU
Mo-T	M1LTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXmyW5FZUUN3ME2xNk44PDJzIN88US=>	MlTSV2FPT0WU
HLE	M1vQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEP0N2ZKSzVyPUGyMlgzOTVizszN	MW\TRW5ITVJ?
RCC10RGB	MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYOyfnd7UUN3ME2xN{43PzFizszN	M1HORXNCVkeHUh?=
COLO-320-HSR	M{\NeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF34XWFKSzVyPUGzMlc{QDFizszN	Mlq4V2FPT0WU
BHT-101	NEDYSIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rYV2lEPTB;MUOuPFM1PSEQvF2=	MU\TRW5ITVJ?
OCUB-M	NIS5PVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HKc2lEPTB;MUSuNVYxOiEQvF2=	M4LWVXNCVkeHUh?=
MEG-01	NFHKOFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHUdnZKSzVyPUG0MlM4ODhizszN	MYPTRW5ITVJ?
RS4-11	Mo\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXT2XoJCUUN3ME2xOE44PDJizszN	MnfDV2FPT0WU
MN-60	NEGz[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nnUWlEPTB;MUSuO\|g6PCEQvF2=	M1XQW3NCVkeHUh?=
NCI-H1304	M{TicWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTF3LkC0NlUh\|ryP	NUXG[Yc4W0GQR1XS
Ramos-2G6-4C10	NHTrT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHkelhbUUN3ME2xOU4xPThzIN88US=>	M1SzOXNCVkeHUh?=
NCI-H2342	NGnhWnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHmTWM2OD1zNT6yNFQ1KM7:TR?=	MUjTRW5ITVJ?
LAN-6	NX7YUYpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkCxTWM2OD1zNT60OFE1KM7:TR?=	MlXqV2FPT0WU
JVM-2	M2P1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLV[3BKSzVyPUG1MlU4PDhizszN	NWqxRpE{W0GQR1XS
P30-OHK	NXPZXGhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHTNXlKSzVyPUG2MlA3OTRizszN	Mle0V2FPT0WU
C-33-A	NFHy[phIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LjXWlEPTB;MU[uOlIyPCEQvF2=	M3GzSXNCVkeHUh?=
RPMI-8866	NETCT4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnFbYtKSzVyPUG2Mlg1QTZizszN	NWHoeJg3W0GQR1XS
NCI-H630	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mkn1TWM2OD1zNj64OVM4KM7:TR?=	NUnIZllVW0GQR1XS
KYSE-140	MmrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XtdmlEPTB;MUeuNlAzQCEQvF2=	NEmyO4VUSU6JRWK=
T84	NHXuVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTF6Lki2PVUh\|ryP	NGG1WIdUSU6JRWK=
KU-19-19	M{fENmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TT[WlEPTB;MUiuPVYxQCEQvF2=	NUKyNFJ{W0GQR1XS
BALL-1	NWWzfFQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTF7LkOzPVkh\|ryP	MY\TRW5ITVJ?
Calu-6	MnjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTF7LkS5NkDPxE1?	MXvTRW5ITVJ?
EGI-1	MmHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTrTWM2OD1zOT61PVgh\|ryP	MonOV2FPT0WU
MFH-ino	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILnNFRKSzVyPUG5Mlc1PTRizszN	NYjqXWFUW0GQR1XS
GB-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlKyTWM2OD1{MD6zOVM2KM7:TR?=	MULTRW5ITVJ?
NCI-H1693	MkD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3BTWM2OD1{MD62OVA2KM7:TR?=	MXvTRW5ITVJ?
SW1116	NX\1N2EyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkX6TWM2OD1{MD65N\|YzKM7:TR?=	M{DZ[XNCVkeHUh?=
H-EMC-SS	NIHCS\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPWTWM2OD1{Mj6wOFUh\|ryP	NF6z[IhUSU6JRWK=
D-502MG	M{D6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mli2TWM2OD1{Mj64NlYyKM7:TR?=	MkG4V2FPT0WU
IA-LM	NVTIcWlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITxUFJKSzVyPUKzMlI1QTNizszN	NXLue5lYW0GQR1XS
SW1463	NHLmZ\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\YdYh6UUN3ME2yN{44QSEQvF2=	NWP2RlkzW0GQR1XS
JAR	Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1m1RmlEPTB;MkSuN\|I6OyEQvF2=	NXjuO\|dOW0GQR1XS
HT	M1zW[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jwNmlEPTB;MkSuOFc2OyEQvF2=	NI\STWVUSU6JRWK=
LCLC-103H	NYnBSmpPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfsTWM2OD1{ND64OFQ6KM7:TR?=	M1vEW3NCVkeHUh?=
SNU-449	MnO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjC[4NKSzVyPUK0Mlg4PDFizszN	M1v5WnNCVkeHUh?=
KE-37	NHvJTVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPpTWM2OD1{NT6wPVI5KM7:TR?=	M2X3VHNCVkeHUh?=
NCI-H1623	NU[1c3JkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zT[2lEPTB;MkeuNVMxOyEQvF2=	Mmr3V2FPT0WU
MOLT-13	NV3YXYxXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLx[VBKSzVyPUK3MlM2OTZizszN	M4npVHNCVkeHUh?=
COLO-741	NGrPS3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrqW4Q4UUN3ME2zNU4{OzN\|IN88US=>	M{XuPXNCVkeHUh?=
NB6	NW\ud\|VwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofRTWM2OD1\|Mj6yPFc3KM7:TR?=	MU\TRW5ITVJ?
MOLT-16	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{D5XGlEPTB;M{OuNFA2PSEQvF2=	NHnu[G9USU6JRWK=
IST-MES1	MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jNPWlEPTB;M{SuNFU1OSEQvF2=	NED0bYxUSU6JRWK=
A4-Fuk	MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4H4fWlEPTB;M{WuNFY3KM7:TR?=	NYXp[HFxW0GQR1XS
CAL-85-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2f0[WlEPTB;M{WuNlgyPyEQvF2=	NWT6b295W0GQR1XS
CCRF-CEM	NVG0R25DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3Xc4I1UUN3ME2zO{4yPTN4IN88US=>	NHy0RlRUSU6JRWK=
HAL-01	MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvNTWM2OD1\|OD60PFg6KM7:TR?=	MnXHV2FPT0WU
HEL	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTR\|LkO0NFkh\|ryP	NWSzeXN1W0GQR1XS
EW-1	M{\Femdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLI[mxjUUN3ME20N{41PzZ6IN88US=>	NIH2XoxUSU6JRWK=
MDA-MB-231	NY\WZ4ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2S1NGlEPTB;NEWuNVE6QSEQvF2=	NEfMcYlUSU6JRWK=
ABC-1	NUTFVZU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jvU2lEPTB;NE[uPFU{QCEQvF2=	NVHjb205W0GQR1XS
NCI-H446	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVK1eFlHUUN3ME20PE42ODV6IN88US=>	MWLTRW5ITVJ?
MHH-PREB-1	NI\rTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrsTWM2OD12OT62NFA4KM7:TR?=	M1:4WXNCVkeHUh?=
DOHH-2	NWDXbYR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTR7Lk[2OVYh\|ryP	MmnTV2FPT0WU
GCT	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjxd45KSzVyPUS5MlY6PzZizszN	MofaV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo

17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. ^[1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. ^[2]

Protocol

Kinase Assay:^[1]	+ Expand Hsp90 binding assays: Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl₂, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:^[1]	+ Expand Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 5 days Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A₄₉₀) of wells not containing cells is subtracted. Percentage of viable cells = (A₄₉₀ of 17-AAG treated sample/A₄₉₀ untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number. (Only for Reference)
Animal Research:^[2]	+ Expand Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6 Formulation: Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle Dosages: ~50 mg/kg Administration: Injection i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (170.73 mM)
	Ethanol	5 mg/mL (8.53 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+corn oil For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Tanespimycin (17-AAG) SDF

Molecular Weight	585.69
Formula	C₃₁H₄₃N₃O₈
CAS No.	75747-14-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	CP127374,NSC-330507, KOS 953

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00577889	Completed	Adenocarcinoma of the Pancreas\|Recurrent Pancreatic Cancer\|Stage IV Pancreatic Cancer	National Cancer Institute (NCI)	March 2008	Phase 2
NCT00546780	Completed	Multiple Myeloma	Bristol-Myers Squibb	February 2008	Phase 3
NCT00093496	Completed	Primary Peritoneal Cavity Cancer\|Recurrent Ovarian Epithelial Cancer\|Stage III Ovarian Epithelial Cancer\|Stage IV Ovarian Epithelial Cancer	National Cancer Institute (NCI)	October 2007	Phase 2
NCT00514371	Completed	Multiple Myeloma	Bristol-Myers Squibb	August 2007	Phase 2\|Phase 3
NCT00779428	Completed	Advanced Malignancies	Bristol-Myers Squibb	July 2006	Phase 2
NCT00773344	Completed	Solid Tumors\|Breast Cancer	Bristol-Myers Squibb	December 2005	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?
Answer:
17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Selective HSP90 Inhibitor

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
Most Potent HSP90 Inhibitor

KW-2478 : HSP90, IC50=3.8 nM.
HSP90 Inhibitor in Clinical Trial

17-DMAG (Alvespimycin) HCl : Phase II for Kidney Cancer.
Newest HSP90 Inhibitor

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

Related HSP (e.g. HSP90) Products

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.
Luminespib (AUY-922, NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.
HSP990 (NVP-HSP990)

NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Elesclomol (STA-4783)

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)

Cited by 20 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tanespimycin (17-AAG) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)

Cited by 20 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tanespimycin (17-AAG) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)